MedTrace Logo

A 36-Week Extension to Protocol ISA04-03

NCT00258713 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 309

Last updated 2008-09-29

No results posted yet for this study

Summary

The purpose of this study is to determine the safety and efficacy of voclosporin in patients with plaque psoriasis.

Conditions

Interventions

DRUG

voclosporin

voclosporin 0.2, 0.3, or 0.4 mg/kg BID

Sponsors & Collaborators

  • Aurinia Pharmaceuticals Inc.

    lead INDUSTRY

Principal Investigators

  • Robert Bissonnette, MD · Innovaderm Research

  • Richard Langley, MD, FRCPC · Eastern Canada Cutaneous Research Associates Ltd.

  • Gilles Lauzon, PhD MD FRCPC · University of Alberta

  • Kim Papp, MD, PhD · Probity Medical Research

  • Neil Shear, MD · Ventana Clinical Research Corporation

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
66 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-09-30
Primary Completion
2006-07-31
Completion
2006-07-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00258713 on ClinicalTrials.gov